elleguro

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Deepa Eveleigh, et al.

Application Serial No.: [to be assigned]

Filed: January 23, 2004

Title:

EXPRESSION PROFILES FOR COLON CANCER AND METHODS OF USE

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

Date: January 23, 2004

Susan M. Pellegrino/

MAIL STOP SEQUENCE COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

SUBMISSION OF SEQUENCE LISTING, COMPUTER READABLE COPY FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

Dear Sir:

Submitted herewith with this new application is a:

- 1. Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. Each Sequence Listing is assigned a separate identifier as required in 37 C.F.R. §1.821(c) and 37 C.F.R. §§1.822 and 1.823.
- 2. A copy of each Sequence Listing submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§1.821(e) and 1.824.
- 3. The computer readable form and paper copy submitted herewith are the same, and introduce no new matter over what is disclosed in the application (37 C.F.R. 1.821(g)).

Respectfully submitted,

Susan M. Pellegrino Attorney for Applicants

Reg. No. 48,972

Date: January 23, 2004

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516-4175 (203) 812-6450 Telephone:

Facsimile:

(203) 812-6459